Evaluation of tumor angiogenesis in patients with non-small cell lung carcinoma

Suciu, Bogdan Andrei; Mezei, T; Z, Pap; Dénes, Lóránd; Hălmaciu, Ioana; Pávai, Z; Brînzaniuc, Klara; Azamfirei, Leonard

doi:10.1515/arsm-2015-0025

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor proliferative activity is usually assessed by Ki-67. CD31 is expressed on blood vascular endothelial cells and is considered as a marker of endothelial proliferation in patients with NSCLC (Suciu et al., 2015 ). Circulating microvascular density of the tumor has been established as prognostic factors in many studies (Nefedova et al., 2016 ).…”

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer

Chen

Zhang

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an anticancer drug. It is an accepted opinion that modifying GEF strong hydrophobicity and poor bioavailability would not only enhance its antitumor effects, but also reduce its side effects. In this study, GEF-loadedpoly(e-caprolactone)-poly(ethyleneglycol)-poly(e-caprolactone) (PCEC) -bearing nanoparticles (GEF-NPs) were prepared by a solid dispersion method and characterized. The particle sizes increased with the increase in GEF/PCEC mass ratio in feed. GEF-NPs (10%) were mono-dispersed, smaller than 24 nm, zeta potential was approximately À18 mV, percentage encapsulation and loading, were more than 9% and 92%, respectively, and drug was slowly released but without a biphasic pattern. Microscopy studies of the optimized formulation confirmed that the prepared nanoparticles are spherical in nature. Cytotoxicity results indicated that cell growth inhibition induced by free GEF and GEF-NPs were dose and time dependent. Compared with free GEF, GEF-NPs enhanced antitumor effects, reduced side effects and significantly prolonged survival time in vivo. CD31, ki-67 and EGFR expression were significantly lower in the GEF-NPs group compared with other groups (p< .05). These findings demonstrated that GEF-NPs have the potential to attain superior outcomes and to overcome complications such as organs toxicity, therapeutic resistance and disease relapse. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer

Chen

Zhang

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Unlike genetic markers, determining serum levels of neutrophils, platelets and lymphocytes are routine tests that are performed in all of these patients and do not involve increased financial costs [15]. Also, it is well known the fact that the inflamation play an important role in the healing process [16][17][18].…”

Section: Resultsmentioning

confidence: 99%

The Importance of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Predicting the Appearance of the Rectal Stenosis or Rectal Obstruction in Patients with Rectal Adenocarcinomas

Hălmaciu¹,

Suciu²,

Vunvulea³

et al. 2020

Rev. Chim.

View full text Add to dashboard Cite

The purpose of this study was to establish a correlation between markers of inflammation and the risk of rectal stenosis or obstruction, in patients with rectal adenocarcinomas. We performed a retrospective observational study on 188 patients diagnosed with rectal adenocarcinomas. We attempted to establish a correlation between the neutrophils to lymphocyte ratio(NLR), platelet to lymphocyte ratio(PLR) levels and the presence of rectal stenosis or rectal obstruction. From 188 patients included in the study, 65 patients had stenotic tumors (34.57% of cases) and 10 patients had occlusive tumors (5.31% of cases). We obtained a statistically significant correlation between the blood levels of neutrophils, lymphocytes, platelets, and the existence of rectal stenosis. (p[0.05). The cutoff value of NLR that correlates with the presence of rectal stenosis was 2.5 (95% CI: 0.426-0.574, AUC: 0.500). As for PLR, the cutoff value correlated with the presence of rectal stenosis was 106,522 (95%CI: 0.428-0.575, AUC: 0.502). We established a statistically significant correlation between NLR, PLR and rectal obstruction (p[0.05). The cutoff value of the NLR that correlates with the presence of rectal obstruction was 4.633 (95%CI: 0.614-0.751, AUC: 0.685). As for PLR, the cutoff value correlated with the presence of rectal stenosis was 345.05 (95% CI: 0.673-0.803, AUC: 0.742). Our study shows that there is a statistically significant correlation between NLR and PLR and the risk of rectal obstruction in patients with adenocarcinomas. It is still necessary to conduct prospective studies on much larger lots of patients to determine the NLR and PLR values that can predict rectal stenosis as well as rectal obstruction.

show abstract

“…There are also authors in the literature who have shown the expansion of cystic veins in patients who had mesocaval shunts, in these cases cystic veins function as collateral drainage pathways [6]. Thus, cholecystic varicose veins are observed in 34% of patients with extrahepatic portal venous obstruction [7][8][9].…”

Section: Resultsmentioning

confidence: 99%